Microorganism for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same

Abstract

The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms.

1 . (canceled)  
     
     
         2 . (canceled)  
     
     
         3 . A pharmaceutical composition comprising at least one microorganism selected from the group consisting of  Acetobacter  sp.,  Leuconostoc  sp.,  Bacillus  sp.,  Lactobacillus  sp.,  Streptococcus  sp.,  Bifidobactedum  sp.,  Lactococcus  sp. and  Pediococcus  sp. bacteria in an amount effective to prevent or treat obesity and a pharmaceutically acceptable carrier, wherein the microorganism converts an oligosaccharide into a polysaccharide:  
     
     
         4 . The pharmaceutical composition according to  claim 3 , wherein said microorganism is selected from the group consisting of  Acetobactor  sp.,  Lactobacillus  sp. and  Lactococcus  sp. bacteria.  
     
     
         5 . The pharmaceutical composition according to  claim 3 , wherein said microorganism is selected from the group consisting of  Acetobacter xylinum, Acetobacter hansenii, Acetobacter pasteurianus, Acetobacter aceti, Leuconostoc  sp.,  Bacillus  sp.,  Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus kefir, Lactobacillus keriranofaciens, Lactobacillus bifidus, Lactobacillus sake, Lactobacillus reuteri, Lactobacillus lactis, Lactobacillus delbrueckii, Lactobacillus helveticusglucos  var.  jugurti., Lactococcus cremoris, Bifidobacterium bifidium, Streptococcus thermophilus  and  Pediococcus  sp.  
     
     
         6 . (canceled)  
     
     
         7 . The pharmaceutical composition according to  claim 3 , which is a formulation suitable for oral administration.  
     
     
         8 . The pharmaceutical composition according to  claim 3 , which is a formulation coated with enteric coating materials.  
     
     
         9 . The pharmaceutical composition according to  claim 7 , which is a formulation coated with enteric coating materials.  
     
     
         10 . A pharmaceutical composition comprising at least one microorganism selected from the group consisting of  Acetobacter  sp.,  Leuconostoc  sp.,  Bacillus  sp.,  Lactobacillus  sp.,  Streptococcus  sp.,  Bifidobactedum  sp.,  Lactococcus  sp. and  Pediococcus  sp. bacteria in an amount effective to prevent or treat diabetes mellitus and a pharmaceutically acceptable carrier, wherein the microorganism converts an oligosaccharide into a polysaccharide.  
     
     
         11 . The pharmaceutical composition according to  claim 10 , wherein said microorganism is selected from the group consisting of  Acetobactor  sp.,  Lactobacillus  sp. and  Lactococcus  sp. bacteria.  
     
     
         12 . The pharmaceutical composition according to  claim 10 , wherein said microorganism is selected from the group consisting of  Acetobacter xylinum, Acetobacter hansenii, Acetobacter pasteurianus, Acetobacter aceti, Leuconostoc  sp.,  Bacillus  sp.,  Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus kefir, Lactobacillus keriranofaciens, Lactobacillus bifidus, Lactobacillus sake, Lactobacillus reuteri, Lactobacillus lactis, Lactobacillus delbrueckii, Lactobacillus helveticusglucos  var.  jugurti., Lactococcus cremoris, Bifidobacterium bifidium, Streptococcus thermophilus  and  Pediococcus  sp.  
     
     
         13 . (canceled)  
     
     
         14 . The pharmaceutical composition according to  claim 10 , which is a formulation suitable for oral administration.  
     
     
         15 . The pharmaceutical composition according to  claim 10 , which is a formulation coated with enteric coating materials.  
     
     
         16 . (canceled)  
     
     
         17 . (canceled)  
     
     
         18 . (canceled)  
     
     
         19 . (canceled)  
     
     
         20 . (canceled)  
     
     
         21 . (canceled)  
     
     
         22 . (canceled)  
     
     
         23 . (canceled)  
     
     
         24 . (canceled)  
     
     
         25 . (canceled)  
     
     
         26 . (canceled)  
     
     
         27 . (canceled)  
     
     
         28 . (canceled)  
     
     
         29 . (canceled)  
     
     
         30 . (canceled)  
     
     
         31 . (canceled)  
     
     
         32 . (canceled)  
     
     
         33 . (canceled)  
     
     
         34 . (canceled)  
     
     
         35 . (canceled)  
     
     
         36 . (canceled)  
     
     
         37 . (canceled)  
     
     
         38 . (canceled)  
     
     
         39 . (canceled)  
     
     
         40 . (canceled)  
     
     
         41 . (canceled)  
     
     
         42 . (canceled)  
     
     
         43 . (canceled)  
     
     
         44 . (canceled)  
     
     
         45 . (canceled)